Are Mannan-binding Lectine Serin Protease-2 and Alpha-1-microglobulin and Bukinin Precursor the Potential Biomarkers of Manic Episode? A Study via Urinary Proetomic Analysis

키워드

참고문헌 (45)

1. Kupfer DJ, "The increasing medical burden in bipolar disorder", JAMA, 293, pp.2528~2530 (2005)
2. Teixeira AL, "Update on bipolar disorder biomarker candidates", Expert Rev Mol Diagn, 16, pp.1209~1220 (2016)
3. Bartoli F, "Update on bipolar disorder biomarker candidates: what about uric acid", adenosine hypothesis?, 2017, pp.17, 105~106
4. de Oliveira GS, "Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients", J Psychiatr Res, 43, pp.1171~1174 (2009)
5. Iria Grande, "The Role of BDNF as a Mediator of Neuroplasticity in Bipolar Disorder", PSYCHIATRY INVESTIGATION, 7(4), pp.243~250 (2010), 대한신경정신의학회
6. Jacoby AS, "Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder-Results from a prospective study", J Affect Disord, 197, pp.167~174 (2016)
7. Rolstad S, "CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment", Eur Neuropsychopharmacol, 25, pp.1091~1098 (2015)
8. Johnston-Wilson NL, "Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium", Mol Psychiatry, 5, pp.142~149 (2000)
9. Maffioletti E, "Micro spies from the brain to the periphery : new clues from studies on microRNAs in neuropsychiatric disorders", Front Cell Neurosci, 8, pp.75~ (2014)
10. Monfrim X, "Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropin-releasing hormone and interleukin-1β?", Bipolar Disord, 16, pp.741~747 (2014)
11. Sandberg JV, "Low neuropeptide Y in cerebrospinal fluid in bipolar patients is associated with previous and prospective suicide attempts", Eur Neuropsychopharmacol, 24, pp.1907~1915 (2014)
12. An M, "Urinary biomarkers of brain diseases", Genomics Proteomics Bioinformatics, 13, pp.345~354 (2015)
13. Chengappa KN, "Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania", Bipolar Disord, 5, pp.1~5 (2003)
14. Pieper R, "Preparation of urine samples for proteomic analysis", Methods Mol Biol, 425, pp.89~99 (2008)
15. Kanli A, "Identification of differentially regulated deceitful proteins in SH-SY5Y cells engineered with Tet-regulated protein expression system", J Cell Biochem, 119, pp.6065~6071 (2018)
16. Butler TAJ, "Misleading westerns : common quantification mistakes in Western blot densitometry and proposed corrective measures", Biomed Res Int, 2019, pp.5214821~ (2019)
17. Bayes A, "Differential diagnosis of bipolar II disorder and borderline personality disorder", Curr Psychiatry Rep, 21, pp.125~ (2019)
18. McIntyre RS, "Differential diagnosis of major depressive disorder versus bipolar disorder:current status and best clinical practices", J Clin Psychiatry, 80, pp.ot18043ah2~ (2019)
19. Menezes IC, "Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder : a systematic and critical review", Behav Brain Res, 357-358, pp.29~38 (2019)
20. Munkholm K, "Cytokines in bipolar disorder : a systematic review and meta-analysis", J Affect Disord, 144, pp.16~27 (2013)
21. Frye MA, "Feasibility of investigating differential proteomic expression in depression : implications for biomarker development in mood disorders", Transl Psychiatry, 5, pp.e689~ (2015)
22. Yoshimi N, "Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder : evidence in support of mitochondrial dysfunction hypothesis", Mol Psychiatry, 21, pp.1504~1510 (2016)
23. Zhang R, "Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls", Comput Struct Biotechnol J, 14, pp.106~116 (2016)
24. Szklarczyk D, "STRING v11 : protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets", Nucleic Acids Res, 47, pp.D607~ (2019)
25. Kidmose RT, "Structural basis for activation of the complement system by component C4 cleavage", Proc Natl Acad Sci U S A, 109, pp.15425~15430 (2012)
26. Foldager L, "Bipolar and panic disorders may be associated with hereditary defects in the innate immune system", J Affect Disord, 164, pp.148~154 (2014)
27. Foldager L, "MBL and MASP-2 concentrations in serum and MBL2promoter polymorphisms are associated to schizophrenia", Acta Neuropsychiatr, 24, pp.199~207 (2012)
28. Woo JJ, "The complement system in schizophrenia: where are we now and what's next?", Mol Psychiatry, 25, pp.114~130 (2020)
29. Wang Y, "Urinary peptidomics identifies potential biomarkers for major depressive disorder", Psychiatry Res, 217, pp.25~33 (2014)
30. Gertow J, "Altered protein composition of subcutaneous adipose tissue in chronic kidney disease", Kidney Int Rep, 2, pp.1208~1218 (2017)
31. Zager RA, "Alpha 1 microglobulin : a potentially paradoxical anti-oxidant agent", Adv Tech Biol Med, 5, pp.238~ (2017)
32. Marín-Méndez JJ, "Differential expression of prostaglandin D2synthase(PTGDS)in patients with attention deficit-hyperactivity disorder and bipolar disorder", J Affect Disord, 138, pp.479~484 (2012)
33. Duncan RE, "Brain arachidonic acid uptake and turnover : implications for signaling and bipolar disorder", Curr Opin Clin Nutr Metab Care, 13, pp.130~138 (2010)
34. Gurvich A, "A role for prostaglandins in rapid cycling suggested by episode-specific gene expression shifts in peripheral blood mononuclear cells : a preliminary report", Bipolar Disord, 16, pp.881~888 (2014)
35. Bellei E, "Discovery of restless legs syndrome plasmatic biomarkers by proteomic analysis", Brain Behav, 8, pp.e01062~ (2018)
36. Biswas S, "Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach", PLoS One, 8, pp.e56246~ (2013)
37. Ditzen C, "Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology", Neuropsychopharmacology, 37, pp.1013~1025 (2012)
38. Perretti M, "Annexin A1 and glucocorticoids as effectors of the resolution of inflammation", Nat Rev Immunol, 9, pp.62~70 (2009)
39. Bruschi M, "Annexin A1 and autoimmunity : from basic science to clinical applications", Int J Mol Sci, 19, pp.1348~ (2018)
40. Leoni G, "Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair", J Clin Invest, 125, pp.1215~1227 (2015)
41. Gussenhoven R, "Annexin A1 as neuroprotective determinant for blood-brain barrier integrity in neonatal hypoxic-ischemic encephalopathy", J Clin Med, 8, pp.137~ (2019)
42. Patel JP, "Disruption in the blood-brain barrier: the missing link between brain and body inflammation in bipolar disorder?", Neural Plast, 2015, pp.708306~ (2015)
43. Beck A, "8th Annual european antibody congress 2012- Nov 27-28, 2012, Geneva, Switzerland", MAbs, 5, pp.339~357 (2013)
44. Moore GL, "Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions", MAbs, 2, pp.181~189 (2010)
45. Berk M, "From neuroprogression to neuroprotection : implications for clinical care", Med J Aust, 193(S4), pp.S36~S40 (2010)

관련 논문AI추천